Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy

BACKGROUND: CAR-T cell therapy is likely to be introduced starting from 2021 in patients with relapsed/refractory myeloma (r/r MM) in Europe. In order to qualify for commercial CAR-T treatment, it is assumed that r/r MM patients will have to be exposed to at least three lines of previous treatments...

Descripción completa

Detalles Bibliográficos
Autores principales: Brechbühl, Simon, Bacher, Ulrike, Jeker, Barbara, Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813277/
https://www.ncbi.nlm.nih.gov/pubmed/33489051
http://dx.doi.org/10.4084/MJHID.2021.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813277/
https://www.ncbi.nlm.nih.gov/pubmed/33489051
http://dx.doi.org/10.4084/MJHID.2021.012

Ejemplares similares